Lamar Health

Here is a fact about the American healthcare system that sounds made up but is not: the drug already exists, the doctor already prescribed it, the patient already needs it - and yet the patient waits. Not because the medicine is rare, but because someone has to fill out a form. Then another form. Then submit both to an insurer through a fax machine, a portal, or an email inbox that may or may not be checked. This is prior authorization, and it is the reason a $70,000-a-year specialty drug can take weeks to reach a person who is sick right now.

Lamar Health is a San Francisco software company that decided this was worth fixing. Its pitch, in the company's own unvarnished words on Y Combinator, is to "take care of shitty paperwork for expensive drugs." That is not the language of a healthcare corporation. It is the language of someone who has actually looked at the workflow and been offended by it. The offense is the whole product thesis.

The economic logic here is elegant, in the way that boring things sometimes are. Specialty medications - the biologics, the infusions, the gene therapies - are enormously expensive, which means insurers guard them with enormously elaborate approval rules. Those rules are not evil, exactly. They are cost control. But cost control implemented by humans retyping payor requirements into six different systems is slow, error-prone, and exhausting. Pharmacies staff up to handle it. They still fall behind. Patients wait anyway.

Lamar's move is to sit in the middle of that mess and automate it. The software pulls in referrals and orders from wherever they arrive - fax, electronic health records, insurer portals, email - and turns four channels of chaos into one structured pipeline. It verifies the patient's insurance coverage. It reads the clinical and payor requirements and checks whether the case actually meets them. Then it submits the prior authorization and tracks it until an answer comes back. The company's stated mission is almost aggressively practical: get patients to treatment faster, without adding headcount.

That last clause is the interesting one. Most efficiency software quietly promises to let you fire people. Lamar frames it differently, and the framing appears to be deliberate. Specialty pharmacies are not overstaffed - they are drowning. The problem is not too many workers; it is too much rework, too many delays, too much burnout, and revenue lost when a fill takes too long. The pitch is not "replace your team." It is "stop making your team do the thing a machine should do."

There is a temptation, looking at a 14-person company with a seed round, to file it under "small." That misreads the situation. Prior authorization is not a niche - it is a tax levied on nearly every expensive prescription in the country, paid in staff hours and patient time. A tool that shaves that tax does not need to be big to matter. It needs to be right about where the friction lives.

Lamar's wager is that the friction lives at intake. Most of the pain in specialty pharmacy is not any single hard decision; it is the accumulated cost of information arriving in incompatible formats and being retyped by tired people. Collapse fax, EHR, portal, and email into one clean pipeline and much of the downstream mess simply stops being generated. That is an unglamorous insight, and unglamorous insights are frequently the durable ones.

The competitive landscape is real. Prior authorization automation has drawn well-funded players - CoverMyMeds, Cohere Health, Rhyme, Myndshft, Develop Health - plus the ever-present alternative of a pharmacy's own operations team doing it by hand. Lamar's edge, such as it is, appears to be focus: not all of healthcare, not every payor interaction, but the specialty and infusion workflow specifically, built by people who understand both the biology and the bureaucracy.

Whether that focus scales into something large is an open question, and an honest profile should leave it open. The company is early, the funding is modest, and the metrics are self-reported. But the problem it has chosen is not going away, the customers it has named are real, and the founder's instinct - that access is a paperwork problem as much as a science problem - is, on the evidence, correct. That is a reasonable place to be building from.